Targets › NFYA
1 program from 1 company in 1 trial: 1 Phase 4; Infectious disease; next expected readout Dec 2027.
Component of the sequence-specific heterotrimeric transcription factor (NF-Y) which specifically recognizes a 5'-CCAAT-3' box motif found in the promoters of its target genes. NF-Y can function as both an activator and a repressor, depending on its interacting cofactors. (UniProt, P23511)
Open in Phaseline: the race on NFYA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Jing Zhou | Ceftazidime Bacterial penicillin-binding protein inhibitor | NFYA | Phase 4 | Ceftazidime-avibactam | Dec 2027 |
Ceftazidime-avibactam (1)
small molecule (1)
Jing Zhou (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.